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other fungi including Penicillium. Methods: We developed a set of
real-time PCR assays for species-speciﬁc detection of 5 medically
important species (A. fumigatus, A. ﬂavus, A. nidulans, A. niger, A.
terreus) that covers 	99% of all Apsergillus infections. In addition
to BLAST analysis, we evaluated cross-reactivity with other As-
pergillus species, and other fungi. Blood specimens were spiked
with serially diluted conidia to establish the dynamic range of
detection. Additionally, to evaluate the clinical utilities of these
assays, we retrospectively analyzed blood from 60 HSCT patients
whose specimens were sent for routine CMV testing. Results: We
identiﬁed individual ITS1 regions that are speciﬁc for each of the
5 Aspergillus species but are conserved among the strains within the
species. Using scorpion technology, each assay ampliﬁed and de-
tected the species-speciﬁc sequence only and no cross-reactivity
was detected when it was challenged with other fungal genomic
DNA. These assays can detect as few as 100 conidia/mL of whole
blood. Of 60 patients analyzed, 2 patients (3%) were Aspergillus-
positive. One patient was positive for A. ﬂavus (1.11 &ttimes; 103
copies/mL), and 1 patient was coinfected with A. ﬂavus (6.40 102
copies/mL) and A. niger (2.70  103 copies/mL). Conclusions:
Developing a real time PCR assay for species-speciﬁc identiﬁcation
of Aspergillus is a major challenge because of signiﬁcant genomic
sequence homology among thousands of common environmental
fungi such as Penicillium. Using scorpion real time PCR assays, we
have identiﬁed Aspergillus infections at the species level in HSCT
patients. Currently, we are evaluating diagnostic utilities of these
assays on retrospective and prospective HSCT patients.
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ROLE OF QUANTITATIVE VIRAL LOAD MONITORING OF BK VIRUS IN
HEMORRHAGIC CYSTITIS COMPLICATING HSCT PATIENTS
Grantham, K.1, Reddy, S.1, Nath, R.12, Visweshwar, N.13, Manna, P.1
1. ViraCor Laboratories, Lee’s Summit, MO; 2. St. Joseph Regional
Medical Center, Patterson, NJ; 3. University of West Virginia Health
Science Center, Morgantown, WV.
Background: Hemorrhagic cystitis (HC) causes signiﬁcant mor-
bidity in hematopoietic stem cell transplantation (HSCT) patients
that could often be life-threatening in post-engraftment. Its inci-
dence varies from 7 to 68%. Polyoma virus BK (BKV) is known to
be associated with the development of HC, however, its diagnosis
could be difﬁcult. We developed a rapid, sensitive, speciﬁc, and
quantitative real time PCR assay and used it for monitoring BKV
infections in HSCT patients with HC. Methods: Primers and a
TaqMan® probe were designed to speciﬁcally amplify and detect
an 83-bp fragment of the BKV Agno gene. We used this assay to
detect and monitor BKV infections in 421 clinical specimens from
86 BMT patients with HC. Results: The real time quantitative
BKV PCR assay is speciﬁc and does not cross-react with other
viruses. Out of 421 clinical specimens from 86 BMT patients, 134
plasma specimens were from 35 patients, 283 urine specimens were
from 78 patients, 4 tissue specimens were from 4 patients, and 27
patients had both urine and plasma specimens. Overall 288 (68%)
specimens from 65 patients (76%) were positive for BKV. More
speciﬁcally, out of 35 patients with plasma specimens, 18 (51%)
had viremia, and out of 78 patients with urine specimens, 62 (79%)
had viruria. Of the 27 patients with both plasma and urine, 14
(52%) had both viruria and viremia, and 12 (44%) had viruria. Two
patients with viruria and viremia also had BKV in tissue, while
another 2 patients with viruria, but not viremia, were negative in
tissue. Urine viral loads (range 2.5  102–9.9  107, mean 7.7 
107, median 1.6  106) were signiﬁcantly higher than plasma
(range 4.0  102–1.5  106, mean 1.2  106, median 6.1  104).
Nineteen patients with HC serially monitored for BKV infections
for over 3 months showed correlations between BKV loads and
clinical symptoms. Interestingly, 4 patients had viruria with in-
creasing BKV loads that ended up with viremia later, indicating
that early BKV screening of urine may provide an early diagnosis
so that treatment therapy can be instituted to avoid severe HC
complications in HSCT patients. Conclusions: Real time BKV
PCR assay provides a rapid, sensitive, and speciﬁc diagnosis of
BKV infections in HC complicating HSCT patients. Furthermore,
quantitative monitoring helps in determining the severity of infec-
tions and measuring the effectiveness of treatment therapy. Cur-
rently, we are monitoring BKV infections in a controlled study on
HSCT patients with HC.
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COMPARISON OF HEATH-RELATED QUALITY OF LIFE IN SIBLING AL-
LOGENEIC TRANSPLANT DONORS USING BONE MARROW OR PERIPH-
ERAL BLOOD
Watanabe, S.1, Kishi, K.1, Shimizu, N.2, Nishimura, M.2,
Fujimaki, K.3, Kanamori, H.3, Mori, T.4, Shimizu, T.4, Yokota, A.5,
Onoda, M.5, Sakai, M.6, Sakamaki, H.6, KSGCT, 7 1. Division of
Hematology/Oncology, Tokai University School of Medicine, Isehara,
Kanagawa, Japan; 2. Department of Clinical Cell Biology, Chiba Uni-
versity Graduate School of Medicine, Chiba, Japan; 3. Department of
Hematology, Yokohama City University Hospital, Yokohama, Kana-
gawa, Japan; 4. Division of Hematology, Department of Medicine, Keio
University School of Medicine, Tokyo, Japan; 5. Internal Medicine,
Chiba Aoba Municipal Hospital, Chiba, Japan; 6. Division of Hematol-
ogy, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; 7. Kanto
Study Group for Cell Therapy, Tokyo, Japan.
Purpose: We have programmed a study to evaluate the differ-
ence in health-related quality of life (QOL) in stem cell transplant
donors harvested by marrow aspiration (BM) or by blood apheresis
after peripheral stem cell mobilization with G-CSF (PB). Meth-
ods: Seventy-four healthy sibling donors from 6 institutes entered
the study. The method of harvest was voluntarily selected by each
donor after information about risks and beneﬁts of both proce-
dures. Standard laboratory tests and subjective QOL assessments
by Short-Form 36 (SF36) were performed 4 times; on the day
before operation or G-CSF administration, the seventh day, the
fourth week, and 3 months after harvest. SF 36 includes 8 catego-
ries of assessment; physical functioning (PF), role-physical (RP),
role-emotional (RE), body pain (BP), general health perception
(GH), vitality (VT), social functioning (SF), and mental health
(MH). Results: Thirty-two BM donors and 42 PB donors entered.
When QOL assessments before procedure were compared, scores
of PF, RP, BP, SF, RE, and MH were lower (P  .05, by Mann-
Whitney test) in BM donors than in PB ones. Lowest scores of
QOL were observed on the seventh day after procedures in both
groups. Statistical differences of scores were signiﬁcant in PF
(65.7  10.2 vs 90.8  14.5), RP (50.5  27.9 vs 83.8  22.2), RE
(54.5  30.2 vs 85.1  19.9), VT (54.4  23.2 vs 68.0  25.1), SF
(61.5 26.5 vs 84.6 20.1), and MH (67.6 19.6 vs 78.8 16.0)
between two groups (BM vs PB, respectively). Scores of QOL
returned to the base value at the fourth week in both groups. QOL
scores of PF, RP, SF, and MH were higher than the base value by
paired t-test in BM donors at 3 months after harvest. Discussion:
Previous blood storage and mental stress before anesthesia and
operation appeared to be the causes of decrease in QOL scores
before harvest in BMT donors. Decrease in scores of PF, RP, BP,
and RE at the seventh day indicates both procedures provide
physical stress on donors, however, grade of decrease was higher in
BM donors than in PB donors.Conclusions: BM donors feel more
stress on emotion and mental health as well as physical condition
than PB donors.
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EXTRACORPOREAL PHOTOPHERESIS (ECP) IN CHILDREN WITH RE-
FRACTORY CHRONIC GVHD: FEASIBILITY AND EFFICACY
Browning, B.1, Collins, J., Thormann, K.1, Duerst, R.1, Kletzel, M.1,
Jacobsohn, D.1 Northwestern University / Children’s Memorial Hospi-
tal, Chicago, IL.
Since 2003, we have used ECP for salvage therapy of pediatric
cGVHD. We developed an algorithm for children of different
weights to guide the need for pRBC transfusion prior to ECP: if
	40 kg, transfuse for hematocrit (hct) 26%; if 25–40 kg, trans-
fuse for hct 32%, if 25 kg, transfuse for hct 35%. Extracor-
poreal Volume (ECV) is graphed and maximum number of cycles
and bowl size is determined. Generally, the 125 mL bowl is used.
Patients 25 kg receive NS bolus prior to ﬁrst cycle and prior to
second cycle as needed. Volume of NS bolus is calculated as
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graphed ECV—15% total body volume. Patients are on a cardiac
monitor and observed during the 3–5 hour treatment. ECP is
performed 2 days in a row. Initially, we started every other week
and now have moved to starting weekly as we have noticed faster
improvement with this schedule. As symptoms improve, ECP
schedule is tapered. Seven patients have been treated (median age
13 years (9–28), 4 males/3 females). Median duration of ECP: 11
months (1–26). The procedure is well tolerated with mild symp-
toms of hypovolemia noted in patients 25 kg. Weight at start of
ECP was median 48 kg (22.2–79). Patients 25 kg have received
about 1 pRBC transfusion/month. All patients had failed standard
therapy with cyclosporine and prednisone in addition to a second-
or third-line agent. All were on prednisone at start of treatment.
Two patients have renal insufﬁciency. An attempt to lower pred-
nisone dose and discontinue other immunosuppression was made
after stabilization of cGVHD. Three patients expired due to
cGVHD complications. Of the remaining 4 patients: 1 is too early
to evaluate, all 3 others have responded, of which 2 have discon-
tinued steroid therapy. Response by organ and steroid doses are
listed below. All patients remain on a tapered schedule of ECP
(every 3 or 4 weeks) since ECP discontinuation led to cGVHD
ﬂares in 2, which responded with reinstitution of ECP. The pa-
tients with scleroderma and oral sensitivity appear to have had
signiﬁcant beneﬁt from ECP. ECP is feasible in pediatric patients
with cGVHD if hct and hydration are carefully maintained at
adequate levels for lower-weight patients. ECP appears to be
efﬁcacious for refractory cGVHD. Prospective studies are needed
to deﬁne treatment duration and schedule, and beneﬁts of using
ECP concurrently with other immunosuppressants. Finally, we
plan on demonstrating feasibility in patients20 kg using a similar
algorithm (Table 1).
Table 1. Pediatric Patients with Refractory CGVHD Treated with
Extracorporeal Photopheresis
Age
(yrs)
Duration
(mos)
Symptoms
at Diagnosis
Most
Recent
Symptoms
Intital and
Most
Recent
PDN
Dose, mg/
kg/d
Line
Type Outcome
Weight at
ECP Start
(kg)
12 7 Eyes,
mouth,
skin >
50%
Eyes-SD.
mouth-
CR, Skin-
PR
2 3 0.6 10F Double
Lumen
CVL
Dead 28.6
18 20 Liver Liver-CR 1.6 3 0 10 F single
lumen
CVL
Alive and
Well
48
20 11 Mouth, Skin
> 75%,
Liver
Mouth-PR,
skin-PR,
Liver-PD
0.5 3 0.5 9.6 F
Vortex
Port
Dead 79
11 3 Pulmonary Pulmonary-
PD
1 3 0.5 10 F
Double
Lumen
CVL
Dead 26
28 26 Skin > 50%
(Scleroderma)
Skin-PR 1 3 0.25 9.6 F
Vortex
port
Alive and
well
60.6
9 14 Skin > 50%
(Scleroderma)
Skin-PR 1 3 0 5 F Yuey
PIV
Placed
Before
Each
ECP
Alive and
Well
22.2
13 1 Liver Too Early
to
Evaluate
1 3 0.67 12 F
Double
Lumen
CVL
Alive and
Well
61.5
SD  stable disease, CR  complete response, PR  partial
response, PD  progressive disease, PDN  prednisone,
%body surface area.
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GRAVES’ DISEASE FOLLOWING UNRELATED UMBILICAL CORD BLOOD
TRANSPLANTATION IN PEDIATRIC PATIENTS
Driscoll, T.A.1, Ciocci, G.H.1, Kurtzberg, J.1 Pediatric Blood & Marrow
Transplant Program at Duke University Medical Center, Durham, NC.
Graves’ disease (GD) is the most prevalent autoimmune disease
in the United States with a peak incidence in the ﬁfth to sixth
decades of life and a female to male predominance of 10:1. In
recipients of allogeneic bone marrow and peripheral blood stem
cell transplants, GD recurs in previously affected recipients, occurs
in unaffected recipients by adoptive transfer of autoimmune thy-
roiditis from an affected donor, and occurs less frequently in
unaffected recipients transplanted with unaffected donors. GD was
diagnosed through laboratory surveillance in 3 male pediatric pa-
tients ages 5.5–14.3 years, 30–60 months after UCBT. All 3
affected patients received grafts from female donors and were full
donor chimeras. None had graft-versus-host disease (GvHD) at
diagnosis with GD. Two were transplanted for metabolic diseases
(ALD, PNP deﬁciency) and 1 for ALL. All were conditioned with
busulfan/ATG  cyclophosphamide (n  2) or melphalan (n  1)
and received cyclosporine and methylprednisolone for prophylaxis
against GvHD. All were off immunosuppression therapy for 	1
year at diagnosis of GD. Treatment with readioactive iodide (n 
2) and Propylthiouracil (n 1) corrected laboratory abnormalities.
The 3 boys were part of a cohort of 265 patients transplanted at our
center between 9/1993 and 9/2004, surviving for 	1 year post
UCBT. Within this group, 55% of the patients had female donors
and 45% had male donors. Interestingly, the three cases of GD
occurred among the 86 male patients who received female-donor
UUCBTs. No cases of GD were seen in female recipients. Neither
the donors nor mother of donors developed autoimmune diseases.
However, given their young ages, absence of disease does not rule
out the possibility of development of this disease several decades
into the future.The development of GD in 3 boys after UCBT
from female donors is interesting. The etiology of Graves’ Disease
remains incompletely understood but genetic susceptibility con-
tributes to the development of disease. One affected patient and its
donor expressed the GD susceptibility allele, HLA-DRB10301,
and conversely, a second affected patient and its donor expressed
the GD protective allele, DRB10701. This could indicate the
presence of other immunologic tendencies towards autoimmune
disease in the cord blood donor or an alloreactive process from
donor or low levels of maternal donor cells contaminating the
UCB graft. Further studies will be necessary to determine the
etiology of GD in these patients.
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RISK FACTORS FOR DEVELOPMENT OF SYMPTOMS AFTER AUTOLO-
GOUS TRANSPLANTATION FOR MULTIPLE MYELOMA
Campagnaro, E.1, Saliba, R.1, Anderson, K.1, Roden, L.1, Mendoza, F.1,
Aleman, A.1, Cleeland, C.1, Weber, D.1, Brown, J.1, Giralt, S.1 Blood
and Marrow Transplantation, University of Texas M.D. Anderson
Cancer Center, Houston, TX.
Background: Multiple myeloma (MM) is the most common
indication for autografting in the United States. Although safe,
autografting can be associated with substantial morbidity due to
the toxic side effects of chemotherapy. Strategies aimed at mini-
mizing symptoms post autografting may result in better tolerance.
The risk factors for symptom development post autografting for
MM have not been well characterized. Purpose: To deﬁne pre-
transplant conditions, which may be predictive of post-transplant
symptom burden.Methods:We performed prospective evaluation
of symptom burden among 64 myeloma patients undergoing au-
tograft at MDACC as well as retrospective review of pretransplant
variables including patient demographics, performance status, al-
bumin, disease status, and Charlson Comorbidity Index (CCI).
Univariate analysis was performed to correlate pretransplant vari-
ables with post transplant symptom burden as deﬁned by M. D.
Anderson Symptom Inventory (MDASI) scores at different time
points post transplant. Results: 64 patients were studied from
6/2000 to 5/2003. Symptom burden increased from baseline to day
0 to nadir, with most patients returning to their baseline by day 30
post transplant. Table 1 summarizes the potential impact of pre-
transplant variables on median MDASI scores at nadir. Patients
with the highest MDASI scores at baseline had the highest MDASI
scores at nadir in quartile analysis (P  .001). Patients with Charl-
son score of 3, age 	 60, 2 microglobulin (2M) 	 3, albu-
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